Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

President Donald Trump’s approval rating has hovered at around 40% for the duration of his term—despite an 11-point drop in views of his handling of immigration, as violent clashes with ICE officers ...